$2.3 B

BEAT Mkt cap, 04-Dec-2018

$100 M

BioTelemetry Revenue Q3, 2018
BioTelemetry Gross profit (Q3, 2018)62.7 M
BioTelemetry Gross profit margin (Q3, 2018), %62.7%
BioTelemetry Net income (Q3, 2018)16 M
BioTelemetry Cash, 30-Sep-201863.1 M
BioTelemetry EV2.4 B

BioTelemetry Income Statement

Annual

usdFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

119.0m111.5m129.5m166.6m178.5m208.3m286.8m

Revenue growth, %

(6%)16%29%7%17%

Cost of goods sold

6.2m5.1m73.1m72.0m114.4m

Gross profit

112.8m106.4m93.5m106.6m172.4m

Gross profit Margin, %

95%95%56%60%60%

Sales and marketing expense

26.3m27.9m28.6m35.3m

R&D expense

7.3m7.1m8.4m11.1m

General and administrative expense

36.6m47.9m55.9m83.0m

Operating expense total

86.0m97.0m111.4m174.1m

EBIT

(6.9m)(4.3m)9.5m18.0m

EBIT margin, %

(5%)(3%)5%9%

Interest expense

4.9m

Pre tax profit

(7.1m)(12.1m)7.9m15.8m(10.4m)

Income tax expense

244.0k(905.0k)(215.0k)(468.0k)37.7m

Net Income

(7.3m)(9.8m)7.4m53.4m(17.1m)

BioTelemetry Balance Sheet

Annual

usdY, 2010Y, 2011Y, 2012Y, 2013FY, 2013Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017

Cash

18.7m18.3m18.3m22.2m22.2m20.0m19.0m19.0m23.1m36.0m

Accounts Receivable

Inventories

2.4m2.6m2.4m2.4m1.5m5.2m5.3m

Current Assets

44.3m44.3m49.5m47.0m47.0m59.6m90.1m

PP&E

18.8m18.8m21.7m25.6m25.6m25.8m49.2m

Goodwill

16.5m16.5m29.6m29.8m29.8m41.1m223.1m

Total Assets

87.5m87.5m124.8m124.1m124.1m199.0m524.6m

Accounts Payable

8.7m8.7m13.2m8.5m8.5m12.4m13.2m

Short-term debt

1.3m1.3m1.3m2.1m

Current Liabilities

19.0m19.0m35.3m23.9m23.9m31.5m51.0m

Long-term debt

21.9m21.9m24.0m198.8m

Total Debt

23.2m23.2m25.3m199.4m

Total Liabilities

20.7m48.2m60.1m274.9m

Common Stock

32.0k

Additional Paid-in Capital

260.6m260.6m267.2m272.1m272.1m281.6m409.5m

Retained Earnings

(193.8m)(193.8m)(203.6m)(196.2m)(196.2m)(142.7m)(158.7m)

Total Equity

66.8m66.8m63.7m75.9m75.9m138.9m249.7m

Debt to Equity Ratio

0.3 x0.2 x0.8 x

Debt to Assets Ratio

0.2 x0.1 x0.4 x

Financial Leverage

1.3 x1.3 x2 x1.6 x1.6 x1.4 x2.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

21.0m12.0m13.5m12.2m12.3m14.8m15.5m22.8m25.4m32.3m25.1m26.9m26.2m36.3m39.4m63.1m

Inventories

3.4m3.0m3.0m2.6m3.0m3.2m2.8m2.9m3.5m3.8m4.3m4.1m6.1m6.4m7.7m8.8m

Current Assets

46.0m40.8m41.8m41.9m42.3m43.5m45.2m51.7m59.0m68.3m64.0m65.9m78.4m98.4m105.2m134.0m

PP&E

17.7m25.0m29.1m29.0m21.4m23.8m25.0m26.3m26.3m26.3m26.4m26.7m56.7m

Goodwill

16.5m25.6m29.5m29.7m29.8m29.8m29.8m29.8m37.2m37.3m41.0m41.0m227.5m223.7m238.3m238.3m

Total Assets

88.7m107.4m118.4m118.1m117.2m120.0m122.4m128.9m156.2m165.2m204.6m204.0m520.7m528.0m548.4m574.2m

Accounts Payable

8.3m14.9m14.4m12.8m12.0m12.0m10.5m10.4m10.6m9.8m12.9m9.2m14.4m16.9m13.8m15.5m

Short-term debt

450.0k450.0k450.0k1.3m1.3m1.3m1.3m1.3m12.8m1.6m1.9m1.5m2.8m3.6m4.4m

Current Liabilities

21.1m30.4m35.8m34.4m27.5m27.5m25.9m24.3m28.6m42.7m33.9m32.4m48.9m50.2m45.9m50.1m

Long-term debt

22.8m22.5m22.3m21.7m36.0m24.2m23.3m22.8m197.8m197.1m195.7m194.6m

Total Debt

450.0k450.0k450.0k24.1m23.8m23.5m22.9m37.3m37.1m24.9m24.6m199.4m199.9m199.3m199.0m

Total Liabilities

22.9m42.6m55.7m54.2m53.1m52.7m50.9m48.3m67.7m70.2m61.7m57.2m252.4m271.7m275.2m278.7m

Additional Paid-in Capital

259.5m262.7m264.6m265.8m267.7m268.7m270.4m272.8m276.5m278.8m285.4m287.6m405.9m411.3m415.7m422.0m

Retained Earnings

(193.8m)(197.9m)(201.9m)(201.9m)(203.7m)(201.5m)(199.0m)(192.2m)(187.9m)(183.8m)(142.5m)(140.8m)(143.1m)(152.7m)(142.3m)(126.3m)

Total Equity

65.7m64.8m62.7m63.9m64.1m67.3m71.5m80.7m88.5m95.0m142.9m146.8m268.3m256.4m273.2m295.5m

Debt to Equity Ratio

0.4 x0.3 x0.3 x0.4 x0.4 x0.2 x0.2 x0.8 x0.7 x0.7 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.2 x0.2 x0.1 x0.1 x0.4 x0.4 x0.3 x

Financial Leverage

1.3 x1.7 x1.9 x1.8 x1.8 x1.8 x1.7 x1.6 x1.8 x1.7 x1.4 x1.4 x1.9 x2.1 x2 x1.9 x

BioTelemetry Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(7.3m)(9.8m)7.4m53.4m(17.1m)

Depreciation and Amortization

12.3m12.6m12.5m14.3m28.6m

Accounts Receivable

(4.6m)(13.0m)(7.7m)

Inventories

340.0k299.0k188.0k(753.0k)665.0k

Accounts Payable

2.4m47.0k(4.7m)3.1m(9.6m)

Cash From Operating Activities

11.3m8.8m14.4m38.9m23.8m

Purchases of PP&E

(8.2m)

Cash From Investing Activities

(8.2m)(26.9m)(13.6m)(36.2m)(177.2m)

Long-term Borrowings

(26.4m)(1.4m)(25.8m)

Cash From Financing Activities

763.0k15.9m(1.8m)1.4m166.5m

Interest Paid

132.0k856.0k1.0m1.3m3.9m

Income Taxes Paid

112.0k148.0k384.0k359.0k1.6m

BioTelemetry Ratios

USDY, 2018

EV/CFO

54.4 x

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

1.9 x
Report incorrect company information

BioTelemetry Operating Metrics

FY, 2015FY, 2016

Patents (Foreign)

81 111

Patents (US)

34 49

Patents Issued

115 160

Trademarks

17 22
Report incorrect company information

BioTelemetry Employee Rating

2.794 votes
Culture & Values
2.5
Work/Life Balance
2.7
Senior Management
2.2
Salary & Benefits
2.9
Career Opportunities
2.2
Source